Last reviewed 2026-04-20 · How we verify

Vosoritide Injection

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Injection site reaction
• Injection site erythema
• Injection site swelling
• Nasopharyngitis
• Vomiting
• Headache
• Pyrexia
• Injection site urticaria
• Viral infection
• Arthralgia
• Upper respiratory tract infection
• Fall

Key clinical trials

• Vosoritide for Selected Genetic Causes of Short Stature (PHASE2)
• A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months (PHASE2)
• A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature (PHASE2)
• A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia (PHASE2)
• An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia (PHASE3)
• An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia (PHASE2)
• A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) (PHASE2)
• Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.